Khare Sharad, Cerda Sonia, Wali Ramesh K, von Lintig Friederike C, Tretiakova Maria, Joseph Loren, Stoiber Debra, Cohen Greg, Nimmagadda Kiran, Hart John, Sitrin Michael D, Boss Gerry R, Bissonnette Marc
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
Cancer Res. 2003 Jul 1;63(13):3517-23.
K-ras mutations occur frequently in colon cancer and contribute to autonomous growth. In the azoxymethane (AOM) model of colon cancer, in addition to K-ras mutations, we have shown that wild-type (WT) Ras can be activated by upstream pathways, including, e.g., signaling by ErbB receptors. Tumors with mutant or activated WT Ras had increased cyclooxygenase-2 (Cox-2) expression. We have also shown that ursodeoxycholic acid (UDCA) prevented AOM-induced colon cancer and suppressed Cox-2 induction. In this study, we examined the role of Ras in Cox-2 inhibition by UDCA. Rats were fed AIN-76A chow alone, or supplemented with 0.4% UDCA, and received 20 mg/kg AOM i.p. weekly x 2 weeks. At 40 weeks, rats were sacrificed, and tumors were harvested. K-ras mutations were assessed by primer-mediated RFLP, allele-specific oligonucleotide hybridization, and direct DNA sequencing. Ras was immunoprecipitated and defined as activated if [Ras - GTP/(Ras - GTP + Ras - GDP)] was >3 SD above normal colonocytes. Cox-2 mRNA was determined by reverse transcription-PCR, and protein expression was assessed by Western blotting and immunostaining. In the AOM alone group, Ras was activated by mutations in 8 of 30 (27%) tumors, and WT Ras was activated in 7 of 30 (23%) tumors. UDCA significantly suppressed the incidence of tumors with mutant Ras (1 of 31, 3.2%; P < 0.05) and totally abolished the development of tumors with activated WT Ras (0 of 10; P < 0.05). In the AOM alone group, Cox-2 was up-regulated >50-fold in tumors with normal Ras activity and further enhanced in tumors with mutant or signaling-activated Ras. UDCA significantly inhibited Cox-2 protein and mRNA levels in tumors with normal Ras activity. In summary, we have shown for the first time that UDCA suppressed the development of tumors with Ras mutations and blocked activation of WT Ras. Furthermore, UDCA inhibited Cox-2 induction by Ras-dependent and -independent mechanisms.
K-ras突变在结肠癌中频繁发生,并促进自主生长。在结肠癌的氧化偶氮甲烷(AOM)模型中,除了K-ras突变外,我们还表明野生型(WT)Ras可被上游途径激活,包括例如ErbB受体的信号传导。具有突变型或活化型WT Ras的肿瘤中环氧合酶-2(Cox-2)表达增加。我们还表明,熊去氧胆酸(UDCA)可预防AOM诱导的结肠癌并抑制Cox-2的诱导。在本研究中,我们研究了Ras在UDCA抑制Cox-2中的作用。给大鼠单独喂食AIN-76A饲料,或补充0.4%的UDCA,并每周腹腔注射20mg/kg AOM,共2周。在40周时,处死大鼠并收获肿瘤。通过引物介导的限制性片段长度多态性(RFLP)、等位基因特异性寡核苷酸杂交和直接DNA测序评估K-ras突变。免疫沉淀Ras,若[Ras - GTP/(Ras - GTP + Ras - GDP)]高于正常结肠细胞3个标准差以上,则定义为活化。通过逆转录聚合酶链反应(RT-PCR)测定Cox-2 mRNA,并通过蛋白质印迹和免疫染色评估蛋白质表达。在仅接受AOM的组中,30个肿瘤中有8个(27%)通过突变激活Ras,30个肿瘤中有7个(23%)激活WT Ras。UDCA显著抑制具有突变型Ras的肿瘤发生率(31个中有1个,3.2%;P < 0.05),并完全消除具有活化型WT Ras的肿瘤发生(10个中有0个;P < 0.05)。在仅接受AOM的组中,在具有正常Ras活性的肿瘤中Cox-2上调>50倍,在具有突变型或信号激活型Ras的肿瘤中进一步增强。UDCA显著抑制具有正常Ras活性的肿瘤中Cox-2蛋白和mRNA水平。总之,我们首次表明UDCA抑制具有Ras突变的肿瘤发生并阻断WT Ras的激活。此外,UDCA通过Ras依赖性和非依赖性机制抑制Cox-2的诱导。